Clotting Defects in Hemorrhagic Complications of Pregnancy
- 1 December 1964
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 36 (6) , 577-583
- https://doi.org/10.1080/00325481.1964.11695361
Abstract
The coagulation defect in premature separation of the placenta, amniotic embolism, and retention of a dead fetus is primarily a defibrination syndrome resulting from pathologic infusion of thromboplastic substances. Secondary fibrinolytic activity, which can occur as a direct result of the clotting process or in response to hemorrhagic shock, causes proteolysis and further loss of fibrinogen and inhibits polymerization of fibrin. However, measures directed largely against this fibrinolytic activity could predispose the patient to severe thrombotic complications. Therefore, therapy should be aimed primarily at replacing the lost clotting factors, inhibiting the hypercoagulable state, and treating shock.Keywords
This publication has 5 references indexed in Scilit:
- HEPARIN TREATMENT OF BLEEDING: Clinical ObservationsThe Lancet, 1963
- PATHOGENESIS OF THE COAGULATION DEFECT DEVELOPING DURING PATHOLOGICAL PLASMA PROTEOLYTIC (“FIBRINOLYTIC”) STATES. I. THE SIGNIFICANCE OF FIBRINOGEN PROTEOLYSIS AND CIRCULATING FIBRINOGEN BREAKDOWN PRODUCTS*Journal of Clinical Investigation, 1962
- Pathogenesis of Hypofibrinogenemia in Placental AbruptionNew England Journal of Medicine, 1959
- FIBRINOGENOPENIC ACCIDENT OF PREGNANCY AND DELIVERY: A SYNDROME WITH MULTIPLE ETIOLOGICAL MECHANISMS*Annals of the New York Academy of Sciences, 1959
- Hemorrhagic States during PregnancyNew England Journal of Medicine, 1955